Switching on survival signalling to drive drug resistance
(Queen Mary University of London) Researchers at Queen Mary University of London have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2018 Category: Cancer & Oncology Source Type: news
Adjuvant Chemo in Endometrial Cancer: Benefit Only for Some Adjuvant Chemo in Endometrial Cancer: Benefit Only for Some
PORTEC-3 results show that adjuvant chemotherapy improves failure-free survival, although not overall survival, in women with stage III high-risk endometrial cancer, but not in less advanced disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Lower Risk of Some Cancers With Oral Contraceptives Applies Across Lifestyles Lower Risk of Some Cancers With Oral Contraceptives Applies Across Lifestyles
Women who use oral contraceptives for at least a decade may be less likely to develop ovarian or endometrial malignancies, and this benefit doesn ’ t seem to be diminished by other lifestyle risk factors, a U.S. study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 31, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Lower risk of certain cancers with the Pill applies across lifestyles
(Reuters Health) - Women who use oral contraceptives for at least a decade may be less likely to develop ovarian or endometrial malignancies, and this benefit doesn ’t seem to be diminished by other lifestyle risk factors, a U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Vaginal Estrogen for GSM and Risk of Endometrial Cancer Vaginal Estrogen for GSM and Risk of Endometrial Cancer
Concerns remain regarding the safety of low-dose vaginal estrogen for the treatment of genitourinary syndrome of menopause. What does the latest evidence show?Menopause (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
